Kenneth Vielsted Christensen

List of Publications by Year
in descending order

32 papers	972 citations	567281 15 h-index	477307 29 g-index
35 all docs	35 docs citations	35 times ranked	1850 citing authors

#	Article	IF	Citations
1	No detectable effect on visual responses using functional MRI in a rodent model of Î±-synuclein expression. ENeuro, 2021, 8, ENEURO.0516-20.2021.	1.9	0
2	Design and Synthesis of Pyrrolo[2,3-d]pyrimidine-Derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Checkpoint Kinase 1 (CHK1)-Derived Crystallographic Surrogate. Journal of Medicinal Chemistry, 2021, 64, 10312-10332.	6.4	21
3	Classification ofÂÎ±-synuclein-induced changesÂin the AAV Î±-synuclein rat model of Parkinsonâ€™s disease using electrophysiological measurements of visual processing. Scientific Reports, 2020, 10, 11869.	3.3	4
4	Progressive Effects of Sildenafil on Visual Processing in Rats. Neuroscience, 2020, 441, 131-141.	2.3	1
5	Nfat5 is involved in the hyperosmotic regulation of Tmem184b: a putative modulator of ibuprofen transport in renal MDCK I cells. FEBS Open Bio, 2019, 9, 1071-1081.	2.3	3
6	Transcriptome analysis identifies activated signaling pathways and regulated ABC transporters and solute carriers after hyperosmotic stress in renal MDCK I cells. Genomics, 2019, 111, 1557-1565.	2.9	20
7	Long-Term Exposure to PFE-360 in the AAV-Î±-Synuclein Rat Model: Findings and Implications. ENeuro, 2019, 6, ENEURO.0453-18.2019.	1.9	4
8	Parkinson's disease-like burst firing activity in subthalamic nucleus induced by AAV-Î±-synuclein is normalized by LRRK2 modulation. Neurobiology of Disease, 2018, 116, 13-27.	4.4	21
9	PFE-360-induced LRRK2 inhibition induces reversible, non-adverse renal changes in rats. Toxicology, 2018, 395, 15-22.	4.2	47
10	Recent Progress in Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors for the Treatment of Parkinson's Disease. Medicinal Chemistry Reviews, 2018, , 67-82.	0.1	1
11	Asc-1 Transporter Regulation of Synaptic Activity via the Tonic Release of d-Serine in the Forebrain. Cerebral Cortex, 2017, 27, bhv350.	2.9	54
12	Design of Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Crystallographic Surrogate Derived from Checkpoint Kinase 1 (CHK1). Journal of Medicinal Chemistry, 2017, 60, 8945-8962.	6.4	41
13	Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease. Progress in Medicinal Chemistry, 2017, 56, 37-80.	10.4	17
14	Selective LRRK2 kinase inhibition reduces phosphorylation of endogenous Rab10 and Rab12 in human peripheral mononuclear blood cells. Scientific Reports, 2017, 7, 10300.	3.3	88
15	The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4500-4505.	2.2	15
16	A mouse model of the schizophrenia-associated 1q21.1 microdeletion syndrome exhibits altered mesolimbic dopamine transmission. Translational Psychiatry, 2017, 7, 1261.	4.8	37
17	Persistent gating deficit and increased sensitivity to NMDA receptor antagonism after puberty in a new mouse model of the human 22q11.2 microdeletion syndrome: a study in male mice. Journal of Psychiatry and Neuroscience, 2017, 42, 48-58.	2.4	63
18	Ibuprofen transport in renal cell cultures: characterization of an ibuprofen transporter upregulated by hyperosmolarity. MedChemComm, 2016, 7, 1916-1924.	3.4	2

#	Article	IF	Citations
19	Abnormal visual gain control in a Parkinson's disease model. Human Molecular Genetics, 2014, 23, 4465-4478.	2.9	39
20	A Mouse Model that Recapitulates Cardinal Features of the 15q13.3 Microdeletion Syndrome Including Schizophrenia- and Epilepsy-Related Alterations. Biological Psychiatry, 2014, 76, 128-137.	1.3	95
21	B17 Characterisation Of A Huntington's Disease Cellular Model For The Transcriptome-based Expression Analysis Of Deubiquitinating Enzymes. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, A14-A15.	1.9	0
22	Function and expression of the protonâ€coupled amino acid transporter PAT1 along the rat gastrointestinal tract: implications for intestinal absorption of gaboxadol. British Journal of Pharmacology, 2012, 167, 654-665.	5.4	30
23	Glucocorticoid Receptor and Myocyte Enhancer Factor 2 Cooperate to Regulate the Expression of c-JUN in a Neuronal Context. Journal of Molecular Neuroscience, 2012, 48, 209-218.	2.3	13
24	Hippocampal CA1 region shows differential regulation of gene expression in mice displaying extremes in behavioral sensitization to amphetamine: relevance for psychosis susceptibility?. Psychopharmacology, 2011, 217, 525-538.	3.1	7
25	Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats. BMC Neuroscience, 2010, 11, 9.	1.9	45
26	Over-expression, purification and characterization of an Asc-1 homologue from Gloeobacter violaceus. Protein Expression and Purification, 2010, 71, 179-183.	1.3	1
27	Support for a bipolar affective disorder susceptibility locus on chromosome 12q24.3. Psychiatric Genetics, 2010, 20, 93-101.	1.1	6
28	Measurement of cellular Î²-site of APP cleaving enzyme 1 activity and its modulation in neuronal assay systems. Analytical Biochemistry, 2009, 387, 208-220.	2.4	7
29	Recruitment of Î²-arrestin2 to the dopamine D2 receptor: Insights into anti-psychotic and anti-parkinsonian drug receptor signaling. Neuropharmacology, 2008, 54, 1215-1222.	4.1	70
30	The dynamics of the LPS triggered inflammatory response of murine microglia under different culture and in vivo conditions. Journal of Neuroimmunology, 2006, 180, 71-87.	2.3	187
31	Correlation of the expression of kainate receptor subtypes to responses evoked in cultured cortical and spinal cord neurones. Brain Research, 2002, 926, 94-107.	2.2	13
32	Larger intercellular variation in (Q/R) editing of GluR6 than GluR5 revealed by single cell RT-PCR. NeuroReport, 2000, 11, 3577-3582.	1.2	7